P-114 The therapeutic potential of nuclear receptor RORy in hepatocellular carcinoma
نویسندگان
چکیده
Globally, hepatocellular carcinoma (HCC) is the fifth most occurring cancer and accounts for second leading cause of cancer-related death. Multiple risk factors lead to development HCC; where Hepatitis B C viruses, alcohol consumption, diabetes nonalcoholic fatty liver disease (NAFLD) play dominant roles. Due poor prognosis inefficiency current treatments (chemotherapy, immunotherapy resection), novel HCC-targeted therapies are critically required patients suffering from disease. RORγ (Retinoic Acid-Receptor-Related Orphan Receptor Gamma) a mammalian nuclear receptor master transcriptional regulator IL-17 cytokine. RORy reported be highly expressed in various cancers, including HCC. It speculated that inhibition with inhibitor (C#10), HCC, will hinder proliferative properties by suppressing cytokine inflammatory tumour microenvironment. This study aims assess effect C#10 on cell proliferation vitro its influence progression vivo. Human (HuH-7) mouse (Hepa1-6) HCC lines were stained anti-RORγ anti-IL-17 antibodies imaged using immunofluorescence microscopy. Western blot was used detect presence protein HuH-7 Hepa1-6 lines. MTT GFP viability assays executed lines, cells subjected 72 hour increasing concentrations (C#10). Colony formation done cells, growth expansion monitored when treated 14 days doses C#10. subcutaneous models daily dose 10mg/kg differences over course 3 weeks. We show express The release also shown visualized both western blot. reveal less viable as increase. decreases model experiments display reduced burden after treatment Statistical analyses performed verify significance all experiments. expresses impedes future findings presented this research project may provide crucial insights beneficial patients. In turn, effective therapy improve patient outcomes, quality life, reduce time spent hospital, health care costs ameliorate meagre survival outcomes.
منابع مشابه
Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis. Sorafenib is the only approved systemic chemotherapeutic drug for patients with advanced HCC. Previous studies have shown that androgen and androgen receptor (AR) are involved in human hepatocarcinogenesis and the development of HCC. Here, we discuss the recent data on AR and HCC, and the combination of sorafenib and...
متن کاملE2F8 is a Potential Therapeutic Target for Hepatocellular Carcinoma
E2F transcriptional factors are widely expressed in a number of tissues and organs, possessing many regulatory functions related to cellular proliferation, differentiation, DNA repair, cell-cycle and cell apoptosis. E2F8 is a recently identified member of the E2F family with a duplicated DNA-binding domain feature discriminated from E2F1-6, controlling gene expression in a dimerization partner-...
متن کاملHepatocellular carcinoma in a sheep
At necropsy of a five-year-old sheep, a pear shaped, lobular yellow-brownish mass measuring about 12 ×15 × 20 cm was found to involve the right hepatic lobe. Microscopic examination revealed two trabecularand solid patterns of neoplastic hepatocytes. In solid pattern, there were numerous tumoral giant cells thatcontain one or more large hyperchromatic bizarre-shaped nuclei scattered among clust...
متن کاملMPHOSPH1: a potential therapeutic target for hepatocellular carcinoma.
MPHOSPH1 is a critical kinesin protein that functions in cytokinesis. Here, we show that MPHOSPH1 is overexpressed in hepatocellular carcinoma (HCC) cells, where it is essential for proliferation. Attenuating MPHOSPH1 expression with a tumor-selective shRNA-expressing adenovirus (Ad-shMPP1) was sufficient to arrest HCC cell proliferation in a manner associated with an accumulation of multinucle...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2023
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2023.04.170